🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "huge turning point" in the fight against superbug strains of the infection, according to health experts.

An International Public Health Issue

The sexually transmitted infection are on the rise around the world, with data suggesting over 82 million instances annually. Especially elevated rates are seen in Africa and nations within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Within England, cases have reached a record high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely advancement in the reality of rising global incidence, the spread of superbugs and the very limited available drugs presently on offer.”

Health officials are particularly alarmed about the rise in antibiotic-resistant strains. The global health body has listed it as a "critical concern". Recent surveillance showed that resistance to primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Treatment Options Secure Authorization

Zoliflodacin, alternatively called Nuzolvence, was approved by the American regulatory agency in mid-December for treating gonorrhoea. This infection can lead to significant complications, including infertility. Researchers hope that targeted use of this new drug will help delay the emergence of superbugs.

Another new antibiotic, originating from the drugmaker GSK, also received approval in concurrent days. This drug, which is additionally indicated for UTIs, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment stemmed from a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to develop it.

“This milestone signifies a significant shift in the management of multidrug-resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Clinical Trial Outcomes and Global Access

As per findings released by a major medical journal, the new drug eradicated the vast majority of cases of the STI. This places it at an equal footing with the existing first-line therapy, which combines a dual-drug approach. The study included over 900 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the authority to register and commercialise the drug in numerous regions with limited resources.

Medical professionals treating patients have shared positive views. Access to a easy-to-administer therapy of this kind is hailed as a "game-changer" for managing the epidemic. This is deemed crucial to alleviate the strain of the illness for patients and to halt the transmission of highly drug-resistant gonorrhoea around the world.